What are the challenges in blinding participants and providers in trials evaluating survival outcomes?

Sep 17, 2024 ... Sarah Howlett discussing the trial design of STAMPEDE2, a phase 3, randomized, open-label trial of niraparib-abiraterone acetate + prednisolone ... This is a first-in-human, Ph 1/2, open-label, multicenter dose escalation and expansion study in advanced solid tumors. Donepezil is an effective and safe drug for the long-term symptomatic treatment of mild to moderately severe AD for up to 144 weeks (2.8 years). Study design. CONSERVE was a 1:1 randomized, controlled, open-label, international, multicenter trial at 22 hospitals and cardiology practices in North America, ... Jan 1, 2025 ... This open-label study suggests efficacy and safety of psilocybin in severe TRD and supports further study of psychedelics in this population ... Open-label trial of Sibeprenlimab for treatment of IgAN. Research type. Research Study. Full title. A Phase 2/3, Multicenter, Open-label Trial to Evaluate the ... Nov 9, 2023 ... Conclusions. These findings suggest that prescribed medical cannabis may have minimal acute impact on cognitive function among patients with ... Study #2024-1042. A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with ... May 23, 2014 ... Open label trials are sometimes referred to as “non-masked” or “unblinded.” If the trial is a non-pharmacological study, such as a trial of ... Open-Label Trial pronounce term ... A type of clinical trial. In open-label trials, both the researchers and participants know which drug (or other intervention) ...